Diagnostic Value of the Biofire®in Community Acquired Pneumonia
1 other identifier
interventional
60
1 country
1
Brief Summary
This study aimed to determine the impact value of the BioFire FilmArray Pneumonia panel compared to conventional sputum culture in critically ill patients with pneumonia.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started May 2023
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 15, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 30, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
April 30, 2024
CompletedFirst Submitted
Initial submission to the registry
May 21, 2024
CompletedFirst Posted
Study publicly available on registry
May 24, 2024
CompletedMay 29, 2024
May 1, 2024
12 months
May 21, 2024
May 26, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
the ICU length of stay
The potential correlation between the use of BFPP and its relation to the ICU length of stay
Five days after admission
Study Arms (2)
Group A: Routine Conventional Methods
ACTIVE COMPARATORPatients subjected to Routine sputum culture Conventional Methods
GroupB: BioFire Pneumonia Panel (BFPP).
ACTIVE COMPARATORPatients subjected to BioFire Pneumonia Panel (BFPP
Interventions
Sputum culture was done to patients and they received Antibiotics According to its results
BioFire Pneumonia Panel (BFPP) was done to patients and they received Antibiotics According to its results
Eligibility Criteria
You may qualify if:
- Patients admitted to the ICU with community acquired pneumonia
You may not qualify if:
- Age less than 18 years old.
- End stage malignant patients,
- Patients admitted to the ICU with Acute Lung Injury (ALI).
- Patients admitted to the ICU with Acute Respiratory Distress Syndrome (ARDS).
- Patients with radiological findings suggesting atypical pneumonia.
- Immunocompromised as defined by HIV/AIDS, known immunodeficiency, chronic steroids \> 20mg/day Prednisone equivalent, other immunosuppressants.
- Solid organ or bone marrow transplant patients, cystic fibrosis.
- Unstable psychiatric or psychological condition rendering the subject unlikely to be cooperative or to complete the study requirements.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Ain Shams University
Cairo, Abassia, Egypt
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, CARE PROVIDER
- Purpose
- DIAGNOSTIC
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Professor
Study Record Dates
First Submitted
May 21, 2024
First Posted
May 24, 2024
Study Start
May 15, 2023
Primary Completion
April 30, 2024
Study Completion
April 30, 2024
Last Updated
May 29, 2024
Record last verified: 2024-05